John A. Josey - 01 Jun 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: Director
Signature: /s/ Charles N. York, II, as Attorney-in-Fact for Reporting Person
Issuer symbol: DAWN
Transactions as of: 01 Jun 2021
Net transactions value: +$112,000
Form type: 4
Filing time: 01 Jun 2021, 21:51:15 UTC
Previous filing: 26 May 2021
Next filing: 23 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Purchase	$112,000	+7,000	+11%	$16.00	72,292	01 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DAWN	Stock Option (right to buy Common Stock)	Award	$0	+63,000		$0.000000	63,000	26 May 2021	Common Stock	63,000	$16.00	Direct	F2, F3
transaction	DAWN	Stock Option (right to buy Common Stock)	Award	$0	+1,181		$0.000000	1,181	26 May 2021	Common Stock	1,181	$16.00	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
F2	The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 26, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3	The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act.
F4	The option vests as to 1/48th of the total shares on each monthly anniversary, beginning on November 6, 2020, subject to the Reporting Person's provision of service to the Issuer on each vesting date.